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The HIV envelope glycoprotein gp160 plays a major role in the posttranslational down-regulation of its receptor, CD4. In
this report we have analyzed the requirements of both CD4 and gp160 involved in transport block of the gp160–CD4
complex causing the down-regulation of cell surface CD4. Using a transient expression system we observed that both
soluble and membrane-bound CD4 were equally blocked by the wild-type gp160, indicating that neither the transmembrane
domain nor the cytoplasmic tail of CD4 affected its interaction with gp160 or exocytic transport block of the complex.
Similarly, deletions of the gp160 cytoplasmic domain or mutation in the transmembrane domain had little effect on its
transport, or its ability to down-regulate CD4 surface expression. Furthermore, substitution of the gp160 transmembrane
domain and cytoplasmic tail with that of the influenza virus hemagglutinin or with a glycophosphatidylinositol moiety did
not affect its ability to bind CD4 and block its transport. However, soluble envelope glycoprotein constructs (either gp120
or soluble gp160) were unable to block CD4 transport to the cell surface despite their binding to CD4 within the ER. Taken
together these results demonstrate that neither the gp160 cytoplasmic tail nor the specific sequences of the transmembrane
region of gp160 nor the membrane anchoring of CD4 were involved in ER retention of the CD4–gp160 complex and that
anchoring of gp160 to the ER membrane was responsible for gp160-mediated cell surface down-regulation of CD4. q 1996
Academic Press, Inc.
The surface glycoprotein of the human immunodefi- and gp41 are subsequently transported to the cell mem-
brane, allowing them to be incorporated into buddingciency virus type 1 (HIV-1) consists of two glycoprotein
virus particles.subunits, gp120 and gp41, formed by posttranslational
Analysis of the intracellular transport of the HIV-1proteolytic cleavage of gp160 (2, 22). The external gp120
gp160 demonstrated that only a small fraction of theportion is responsible for binding of the virus to its cellu-
gp160 precursor is cleaved and transported to the celllar receptor CD4, while the transmembrane anchoring
surface (22, 24). The majority is retained within the intra-subunit, gp41, is essential for mediating membrane fu-
cellular compartments and subsequently degraded in ly-sion (10, 18). The subunits of the HIV envelope glycopro-
sosomes. The reasons for this inefficient transport aretein are held together by weak noncovalent interaction.
not completely understood. Since it has been shown thatAs a result, a large proportion of gp120 is shed from the
only correctly folded molecules are transported out ofsurface of cells or viruses into the culture medium (22).
the ER (22), the inefficient transport of gp160 may be dueAs with most other viral glycoproteins, the HIV-1 enve-
to inherent difficulties in the folding of the highly disul-lope proteins are initially synthesized as a precursor pro-
fide-bonded ectodomain. In addition, several laboratoriestein, gp160, which undergoes within the ER extensive
have also demonstrated that for a number of viruses,intramolecular disulfide bonding, followed by acquisition
including HIV, the cytoplasmic tail of the envelope glyco-of high mannose carbohydrate structures, CD4 binding
protein can have a dramatic influence on its transport (5,competency, and oligomerization (7). Subsequently, dur-
6, 12, 21).ing its transport through the Golgi complexes, gp160 un-
Interaction of gp160 with CD4 within the ER also af-dergoes proteolytic cleavage and addition of complex
fects the transport of both molecules to the cell surfaceoligosaccharide side chains (24). This results in the pro-
(3, 14). These gp160–CD4 complexes become trappedduction of mature gp120 which contains high mannose,
within the ER, resulting in receptor interference and su-hybrid, and complex carbohydrate structures (11). gp120
perinfection immunity (25). Although gp160-mediated re-
ceptor interference plays an important role in virus biol-
ogy and pathogenesis, the mechanism by which gp1601 To whom reprint requests should be addressed.
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inhibits the transport of its cellular receptor, CD4, is not CD4 (data not shown). These results showed that in
coexpressing cells, WT CD4 bound to soluble gp120completely understood. Recently, we have reported that
the domains of both proteins involved in intracellular in- was able to transport through the Golgi and acquire
complex sugars. These results were also confirmed byteraction are different from those involved in cell surface
interaction (19). In this report, we have analyzed the do- the presence of cell surface CD4 using indirect immu-
nofluorescence (data not shown). Similar results weremains of both CD4 and gp160 responsible for the trans-
port block of the intracellular complex and down-regula- also obtained with the soluble gp160 (gp160DTM)
lacking the cytoplasmic tail and transmembrane buttion of the CD4 surface expression.
To determine if CD4 transmembrane or cytoplasmic retaining the entire gp160 ectodomain (19). We ob-
served that gp160DTM was capable of binding CD4sequences play any role in the transport-block of the
CD4 – gp160 complex, we constructed a plasmid intracellularly, but failed to block the transport of CD4
to the cell surface. In cells coexpressing membrane-(psCD4) encoding soluble CD4 (sCD4), which lacks
transmembrane and cytoplasmic tail domains, by plac- bound CD4 and gp160DTM, CD4 was transported to
the surface and became endo H resistant (19). Theseing in phase termination codons before the transmem-
brane domain. We then cotransfected this construct results were consistent with a previous report (3) that
gp41 sequences and/or membrane binding were notinto HeLa cells with and without plasmids encoding
the wild-type (WT) gp160 (pGENV-7N) (14). At 16 hr important in interaction with CD4 but were important
in gp160-mediated sequestration of CD4 within the ER.posttransfection (hpt), the cells were pulse-labeled
with [35S]methionine and [35S]cysteine for 30 min and The results presented above suggest that the cyto-
plasmic and/or transmembrane domains of gp160 werechased with excess unlabeled methionine and cys-
teine for various times. At the end of each time point, critical not for interacting with intracellular CD4 but for
blocking the transport of CD4–gp160 complex to the cellboth the medium and cell lysate were immunoprecipi-
tated using either OKT4 (anti-CD4) or anti-gp41 mono- surface. Since an earlier study has suggested that the
cytoplasmic tail of gp160 may possess an ER retentionclonal antibodies (19) and analyzed by SDS – PAGE (17,
19). The results showed that sCD4 expressed alone signal (12) and therefore may play an important role
in CD4 surface modulation, we constructed three cyto-was secreted efficiently in the medium within 2 hr of
chase. However, when coexpressed with the WT plasmic tail mutants of gp160, namely, gp160D56,
gp160D98, and gp160D147, terminating at residues 800,gp160, very little sCD4 was secreted into the medium
even after 4 hr of chase, and the intracellular sCD4 758, and 709, respectively. Sequences from 770 to 794
and 824 to 856 have been implicated in forming amphi-was coprecipitated with gp160 using either OKT4 or
anti-gp41 antibody and remained completely endo H pathic helix and membrane binding (26) and therefore
may influence intracellular transport. We expressed eachsensitive after 4 hr chase (data not shown). These re-
sults show that sCD4, like the WT CD4, interacted with of these mutants alone to evaluate their transport compe-
tence. Accordingly, HeLa cells transfected with 160D147,gp160 and was blocked in intracellular transport, and
that the cytoplasmic and transmembrane domains of 160D98, and 160D56 mutants were pulse-labeled and
chased for 3 hr. Cell lysates and media supernatantsCD4 did not play a significant role in either CD4 – gp160
complex formation or ER retention of the gp160 – CD4 were immunoprecipitated with anti-gp120 antibody and
analyzed by SDS–PAGE. Each of the mutants were ex-complex.
Next, we investigated the role of cytoplasmic and pressed and transported similarly to the WT gp160 and
similar amounts of gp120 were recovered from the me-transmembrane domains of gp160 in causing the
transport block of the complex. Accordingly, plasmids dium, indicating that the cleavage of gp160 r gp120 and
gp41 in these mutants was similar to that of the WTencoding soluble gp120 (gp160D41) or soluble gp160
(gp160DTM) (19), lacking the transmembrane and cy- gp160 (data not shown).
We then coexpressed each of these cytoplasmic tailtoplasmic tail of gp160, were constructed and
transfected into HeLa cells alone or cotransfected with deletion mutants with the WT CD4 to evaluate their ability
to bind and block CD4 maturation (Fig. 1). Accordingly,WT CD4. At 16 hpt, cells were labeled for 30 min with
[35S]methionine and [35S]cysteine and chased for 2.5 HeLa cells were cotransfected with cDNAs encoding
gp160 cytoplasmic tail truncations and WT CD4, pulse-hr. Both the cell lysate and medium were immunopre-
cipitated with OKT4 or anti-gp120 antibody, treated labeled for 30 min, and chased for 3 hr. Cell lysates
were prepared, and aliquots were precipitated either withwith or without endo H, and analyzed by SDS – PAGE.
The results demonstrated that gp120 – CD4 complexes OKT4 or with anti-gp41 or anti-gp120 antibody. Results
showed that each of the constructs when coexpressedwere precipitated from cell lysates by either OKT4 or
anti-gp120 antibody and the CD4 coprecipitated by with the WT CD4 resulted in the formation of CD4–gp160
complexes which were coprecipitated by OKT4 (Fig. 1,anti-gp120 antibodies was predominantly (70%) endo
H resistant. gp120 was also secreted equally in the lanes 1, 2, 5, 6, 9, and 10) or anti-HIV glycoprotein anti-
bodies (Fig. 1, lanes 3, 4, 7, 8, 11, and 12). Endo H diges-medium when expressed alone or coexpressed with
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Previous reports have suggested that mutation of a
conserved arginine residue at position 696 in the trans-
membrane domain of gp160 can influence the pro-
cessing and transport of HIV-1 and other viral glycopro-
teins (1, 4, 12). Therefore, a gp160 mutant (696R-L) con-
taining an arginine to leucine substitution was expressed
alone or coexpressed with CD4 in HeLa cells. Following
pulse-label and 3-hr chase, cell lysates were immunopre-
cipitated with OKT4 or anti-gp41 or anti-gp120 as de-
scribed above. gp160 696R-L mutant transfected alone
was expressed and exhibited transport behavior similar
to that of the WT gp160 (data not shown). When gp160
696R-L was coexpressed with CD4, gp160–CD4 com-
plexes were precipitated by OKT4 or anti-gp41 (Fig. 1).
More importantly, endo H treatment demonstrated that
the CD4 molecules within these complexes were pre-
dominantly endo H sensitive even after 3 hr chase (Fig.
1), suggesting that arginine at position 696 was not a
critical factor for either intracellular transport of gp160 or
complex formation with CD4 or transport block of the
complex.
The finding that WT gp160 blocked the transport of CD4
while soluble gp120 or gp160D41 failed to block the trans-
port of CD4 from ER, even though both of these proteins
formed intracellular complexes with CD4, led us to investi-
FIG. 1. Coexpression of WT gp160 and cytoplasmic tail mutants gate the role of the anchor domain of gp160 in causing the
(gp160D147, gp160D98, and gp160D56) and transmembrane mutant transport block of CD4–gp160 complexes. Two possibilities
(696R-L) with the WT CD4. HeLa cells were infected with vTF7-3 (m.o.i.
existed: either the specific sequences in the transmem-1) and then cotransfected with CD4 and gp160 cytoplasmic tail deletion
brane region were required or the membrane anchoring ofmutants as reported previously (19). At 16 hpt the cells were pulse-
the gp160 ectodomain per se was critical for the transportlabeled for 30 min and incubated in chase medium for 3 hr. Cell lysates
were divided equally and immunoprecipitated using OKT4 (lanes 1, 2, block of the gp160–CD4 complex. To examine the possible
5, 6, 9, and 10) or anti-gp41 or (lanes 3, 4, 7, and 8), or anti-gp120 influence of the specific sequence in the transmembrane
antibodies (lanes 11 and 12). Precipitates were divided in half and
domain of gp160 on CD4 binding and transport, we madedigested with 10 mU endo H for 12–16 hr at 377 (/) or mock digested
two constructs: In gp160-HA, the ectodomain of gp160 was(0). (*) Indicates the position of endo H sensitive proteins. Positions
linked to the transmembrane and cytoplasmic domain ofof molecular weight markers (in thousands) are shown at the left. The
DNAs used to transfect the cells are indicated above the lanes. Arrow- the influenza hemagglutinin (HA) glycoprotein. In gp160-PI,
heads indicate position of partially endo H resistant CD4. Truncation the ectodomain of gp160 was linked to the glycosylphos-
mutant gp160D56 was created by digestion of pGENV-7N with PstI,
phatidylinositol (GPI) anchor sequences from the decay-followed by isolation of a 2.5-kb fragment and religation. Construct
accelerating factor (DAF). When these constructs were ex-gp160D98 was created by digesting pGENV-7N (14) with BamHI fol-
pressed in HeLa cells alone and assayed by immunopre-lowed by partial digestion with BglII. The 5.1-kb fragment lacking the
coding region of the last 98 amino acids of gp41 was isolated and cipitation, both gp160-HA and gp160-PI were expressed
recircularized. gp160D147 was created by introduction of two prema- and cleaved to levels similar to that of the WT gp160, as
ture in frame stop codons immediately after amino acid 709. Site-
evidenced by the release of similar levels of gp120 in thedirected mutagenesis was performed using the Sulptor in vitro muta-
medium (data not shown). These results were also con-genesis kit (Amersham) and the synthetic oligonucleotide GCG-
firmed by indirect immunofluorescence data which demon-GGTCTGAAATGACAATGGTGAGTATCACTACCTAACTCTATTCAC. The
gp160 696R-L substitution mutant was generated by site-directed muta- strated that gp160 expressed from these constructs was
genesis using the synthetic oligonucleotide GCACAGCAAAAACTATCA- present at the surface of the cells at levels similar to that
ATAAACCTACCAAGCC.
of the WT gp160 (data not shown).
We then coexpressed these gp160 chimeric proteins
with the WT CD4 in HeLa cells and assayed for thetion revealed that CD4 remained predominantly endo H
sensitive during chase, as was observed in cells cotrans- presence of CD4 – gp160 complexes as described
above. Both gp160-HA and gp160-PI were capable offected with the WT gp160, indicating that the transport
of CD4 through the Golgi was inhibited (Fig. 1). Thus, forming intracellular complexes with CD4, which were
precipitated by OKT4 or anti-gp120 antibodies. CD4deletion of the gp160 cytoplasmic tail did not influence
either the transport of gp160 or its ability to bind and in these complexes remained predominantly endo H
sensitive, indicating that the majority of CD4 in theseinterfere with the transport of CD4.
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experiments was blocked at the ER (Fig. 2). In autora-
diographs of some samples precipitated with poly-
clonal anti-gp120 antibody, varying amounts of a band
appeared in the same position as that of the endo H
resistant form of CD4 (#, Fig. 2, lane 1). Because of
the presence of this nonspecific band, the results were
somewhat variable. However, CD4 was predominantly
endo H sensitive in repeated coexpression experi-
ments. These results indicate that membrane anchor-
ing of gp160 rather than sequence specificity of the
transmembrane domain was predominantly responsi-
ble for the transport block of the gp160 – CD4 complex
in the ER, causing modulation of cell surface expres-
sion of CD4.
In order to confirm these biochemical data we as-
sayed for the ability of these gp160 mutants to reduce
the expression of CD4 at the cell surface by indirect
immunofluorescence (19). Accordingly, HeLa cells (2
1 105 cells/well) were grown overnight on chamber
slides. The cells were infected with vTF7-3 and then
cotransfected with pGCD4 and each of the gp160 mu-
tant constructs. At 16 hpt, the transfected cells were
washed with PBS/ and fixed with formaldehyde. Fixed
cells were incubated with OKT4 (1:100 in PBS-G), fol-
lowed by incubation with FITC – goat anti-mouse (1:100
in PBS-G) (19). Expression of CD4 alone resulted in
strong surface expression, which was inhibited by
coexpression with WT gp160 (Fig. 3, compare A and B).
Coexpression of CD4 with each of the gp160 mutants
including gp160-HA and gp160-PI clearly resulted in
decreased surface expression of CD4 when compared
to CD4 expressed alone (Figs. 3C – 3H), although there
was some variation with different gp160 constructs.
Permeabilization of cotransfected cells demonstrated
that the expression level of CD4 and gp160 mutantsFIG. 2. Coexpression of gp160-HA and gp160-PI chimeric constructs
with wild-type CD4. HeLa cells were infected with vTF7-3 (m.o.i. 1) was similar in all transfected cultures (data not shown).
and then transfected with gp160-HA and gp160-PI chimeric constructs On the other hand, coexpression of CD4 with soluble
alone or cotransfected with CD4. At 16 hpt the cells were pulse-labeled gp120 did not cause any inhibition of surface expres-for 30 min and incubated in chase media for 3 hr. Cell lysates were
sion of CD4 (data not shown). These results confirmeddivided and immunoprecipitated using polyclonal anti-gp120 antibodies
that the mutations in gp160 did not prevent the mutant(lanes 1, 2, 5, and 6) or anti-CD4 (lanes 3 and 4) antibodies. Precipitates
were divided in half and digested with 10 mU endo H for 12–16 hr at gp160 from binding and modulating the transport of
377 (/) or mock digested (0). (*) Indicates the position of endo H CD4 to the cell surface.
sensitive proteins. (#) Indicates the position of a nonspecific band (lane In general, productively infected cells are resistant1). Positions of molecular weight markers (in thousands) are shown at
to superinfection by the same retrovirus or other vi-the left. The DNAs used to transfect the cells are indicated above the
lanes. Arrowheads and l indicate position of partially endo H resistant
CD4. Note the compression of the l band due to excess of an unla-
beled protein in this position (lane 5). For construction of gp160-HA, as an EcoRI/BamHI fragment, under the control of the T7 polymerase
M13 mp18 containing the hemagglutin (HA) gene of influenza A/WSN/ promoter to form pGENV-7N-Bst. pGHA-Bst was restricted with BstEII
3 was mutated to introduce a BstEII site starting at nucleotide 1607, at and EcoRI and a 2.9-kb fragment, containing the HA transmembrane
the junction between the ectodomain and the transmembrane domain, and cytoplasmic tail sequences linked to pGEM3, was isolated. pGENV-
using the synthetic oligonucleotide GGAATCAATGGGGGTAACCCA- 7N-Bst was restricted with EcoRI and BstEII, and a 2.0-kb fragment
GATTCTGGCGATCTCTAAACTGTCG. M13 mp18-HA-Bst which con- isolated. This 2.0-kb EcoRI/BstEII fragment was subcloned into the 2.9-
tains the mutated HA, was restricted with BamHI and the 1.7-kb HA kb fragment from pGHA-Bst to form gp160-HA. For construction of
fragment was subcloned into pGEM-3 (Promega), to create pGHA-Bst. gp160-PI, pSM-HXB2PI (27) was restricted with EcoRI and the 3.2-kb
M13 mp18 containing the gp160 gene was used to introduce a BstEII fragment containing envelope sequences linked with a glycosylphos-
site at nucleotide 2064 by site directed mutagenesis using the synthetic phatidylinositol (GPI) anchor from decay accelerating factor (DAF) was
oligonucleotide CCTACTATCATTATGAATATGGTTACCGACCACAGC- isolated. This EcoRI fragment was subcloned into pGEM-3 under the
CAGTTTGTTATGC. The mutated gp160 was subcloned into pGEM-3 control of the T7 polymerase promoter.
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plex formation can impair CD4 cell surface expression
in a concentration-dependent fashion. HeLa cells
transfected with both CD4 and gp160 contain com-
plexes of these molecules which become blocked
within the ER, preventing the transport of CD4 to the
cell surface (3, 14). Studies reported here and pre-
viously (3) demonstrated that the coexpression of solu-
ble gp120 with WT CD4 results in intracellular com-
plexes which traffic normally to the cell surface, sug-
gesting that sequences within the cytoplasmic or
transmembrane domain of the envelope glycoprotein
may be responsible for the ability of gp160 to modulate
CD4 transport. The possible role of the gp160 cyto-
plasmic tail in inhibiting the transport of gp160 and
thus modulating the transport gp160 – CD4 complex
was also suggested by Haffar et al. (12). They demon-
strated that sequences in the cytoplasmic tail of gp160,
between amino acids 751 and 856, can act as a reten-
tion signal inhibiting the transport of gp160 from the
ER to the Golgi. However, results presented here do
not support these conclusions. Tail minus gp160 mu-
tants lacking 56, 98, or 147 amino acids of the gp160
cytoplasmic tail were cleaved and transported ineffi-
ciently, similarly to the WT gp160. Upon coexpression,
these tail minus mutants formed CD4 – gp160 com-
plexes and blocked CD4 transport though the exocytic
pathway. (Fig. 1 and Fig. 3). Our finding, however, is
consistent with more recent studies which have found
no difference in transport between WT gp160 and mol-
ecules containing cytoplasmic tail deletions or trunca-
tions (8, 9, 13). Thus, it does not appear from our results
that cytoplasmic sequences within gp160 are respon-
sible for its inefficient transport, or its ability to form
complexes and retain CD4 within the ER.
The possibility also existed that transmembrane
(TM) sequences may also be playing a role in the abil-
ity of gp160 to sequester CD4 since HIV-1 gp160 con-
tains a conserved arginine (696R) in the middle of its
TM domain. Others have shown that incorporation of
FIG. 3. Cell surface staining of CD4 in HeLa cells coexpressing CD4 a charged amino acid in the TM domain of other viral
and gp160 mutants. HeLa cells were grown on chamber slides for at
glycoproteins interferes with their export to the cellleast 12 hr. Cells were then infected with vTF7-3 and transfected alone
surface (1, 4). Thus, it has been speculated that thiswith cDNA encoding CD4 (A) or cotransfected with wild-type gp160 (B)
or mutant gp160 constructs (C – H). At 16 hpt cells were fixed with 4% charged amino acid in the TM domain of gp160 may
formaldehyde for 10 min and then incubated in PBS-G 12–16 hr at 47. be contributing to poor transport kinetics of gp160.
Slides were incubated sequentially with OKT4 and FITC-conjugated However, a nonconservative substitution mutation of a
goat anti-mouse antibody (19). (A) pGCD4; (B) pGCD4 / pGENV-7N;
conserved arginine at position 696 (R-L) within the TM(C) pCGCD4 / gp160 696R-L; (D) pGCD4 / gp160D147; (E) pGCD4
domain of gp160 failed to increase the transport and/ gp160D98; (F) pGCD4 / gp160D56; (G) pGCD4 / gp160-HA; (H)
pGCD4 / gp160-PI. processing of gp160. Similarly, exchanging the trans-
membrane domain and cytoplasmic tail of gp160 with
that of influenza virus hemagglutinin (gp160-HA) orruses which use the same receptor. This superinfec-
tion immunity, or receptor interference, is caused, in with the glycosylphosphatidylinositol linkage se-
quence from DAF failed to enhance either the transportpart, by the intracellular sequestration of viral recep-
tors. In the case of HIV-1, it is clear from a number or cleavage of gp160. Furthermore, coexpression ex-
periments demonstrated that these gp160 mutants, likeof studies that the envelope glycoprotein of HIV-1
is an important factor in the development of superinfec- the WT gp160, were capable of binding to CD4 and
blocking its transport to the cell surface.tion immunity (15, 25). Intracellular CD4 – gp160 com-
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TABLE 1 substitution within the second conserved domain of
gp120 impairs the export of gp160 from the ER. ThisRole of gp160 or CD4 Mutants in Receptor Interference
hypothesis assumes that intracellular CD4 binding to
Ability to cause gp120 and gp160 are different. Evidence for this can
transport block of be found in the results presented in a recent paper
Mutant CD4:gp160 complex (19) that gp160 mutants which bind CD4 intracellularly
do not bind CD4 at the cell surface when expressed asWT gp160 Yes
soluble gp120 molecules. Additional evidence comes696R r L Yes
gp160D56 Yes from studies by Moore et al. (20), who demonstrated
gp160D98 Yes that the affinity of gp120 for sCD4 depends on whether
gp160D147 Yes the gp120 is soluble or membrane bound. These subtle
gp160-HA Yes
differences in binding may result in the transport differ-gp160 PI Yes
ences seen between gp120 – CD4 complexes andgp160D41a No
gp160DTM No gp160 – CD4 complexes. Clearly, the mechanisms re-
WT CD4 Yes sponsible for gp160-mediated receptor interference
Soluble CD4 (anchor minus) Yes are unknown at this time. These studies indicate that
membrane anchoring of gp160 ectodomain plays a crit-a The same as gp120 (19).
ical role in inhibiting the transport of the CD4 – gp160
complex from ER and thus modulating the surface ex-
pression of CD4.Taken together, these results (Table 1) suggest that
membrane anchoring rather than specific sequences
within the TM or cytoplasmic domain were predomi- ACKNOWLEDGMENTS
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